Screening and early—detection of lung cancer
Open Access
- 1 September 2012
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 23 (suppl_10), x320-x327
- https://doi.org/10.1093/annonc/mds303
Abstract
The greatest news of the past year in this field was the first large-scale early detection trial that could prove a 20% reduction in lung cancer-related mortality by screening high-risk individuals with low-dose computed tomography (LDCT). Several expert groups and medical societies have assessed the data and concluded that LDCT screening for lung cancer is, however, not ready for large-scale population-based implementation. Too many open questions remain, such as definition of the at-risk population, timing and intervals of screening, optimal method of acquisition and interpretation of the images, how to handle (false) positive findings, and especially cost-effectiveness in relation to other lung cancer prevention strategies, mainly smoking cessation. Further analyses and several ongoing European trials are eagerly awaited. Much hope also resides in the use of biomarkers, as their use in, e.g., blood or exhaled air may provide more easy-to-use tests to better stratify high-risk populations for screening studies. While exciting research is ongoing in this domain—e.g. with microRNAs—none of the tests has yet reached sufficient validation for clinical use. Early central lung cancers are more difficult to visualise by CT. For these patients, standard bronchoscopy, complemented by autofluoresence endoscopy, has been studied in different screening and follow-up settings.This publication has 53 references indexed in Scilit:
- Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United StatesJournal of Thoracic Oncology, 2011
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningThe New England Journal of Medicine, 2011
- MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancerProceedings of the National Academy of Sciences of the United States of America, 2011
- Clinical validation of an autoantibody test for lung cancerAnnals of Oncology, 2010
- Technical validation of an autoantibody test for lung cancerAnnals of Oncology, 2010
- Natural history of bronchial preinvasive lesionsCancer and Metastasis Reviews, 2010
- Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study DesignJNCI Journal of the National Cancer Institute, 2008
- Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseasesCell Research, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008
- Risk‐based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch‐Belgian randomised lung cancer multi‐slice CT screening trial (NELSON)International Journal of Cancer, 2006